Cannabis
PharmaCielo Announces First Shipment of Pharmaceutical Grade Cannabis Extract to Customer in Morocco
PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. (“Holdings”), today announced that it has made an initial shipment of CBD Isolate to a pharmaceutical company in Morocco, to facilitate pre-commercial testing. The customer is developing a portfolio of cannabinoid medicines, both non-psychoactive, and psychoactive.
Bill Petron, CEO of PharmaCielo, commented, “With our first shipment to Morocco, PharmaCielo products are now at various stages of testing and sales with customers in 12 countries globally. This customer provides us with both our first potential relationship in Africa, as well as an additional gateway to the EU market. Our business development team has done an outstanding job of getting PharmaCielo into the testing and auditing phases at several large potential customers, and we expect this activity to translate into commercial deals in the coming months, paving the way to significant revenue growth for the Company.”
The Company also announced that it intends to issue, subject to the approval of the TSX Venture Exchange, 1,349,016 common shares of the Company (“Interest Shares”), at an effective price of $0.3704 per Interest Share, in satisfaction of an aggregate of $499,657.67 in semi-annual interest payments due to holders of 11% secured debentures of the Company due December 24, 2024 (the “Debentures”). The effective price of the Interest Shares was determined by dividing the cash interest otherwise payable, by the number of shares issuable under each Debenture, as determined on December 1, 2022, in accordance with the terms of the Debentures.
Today, the Company also announced that it intends to issue, subject to the approval of the TSX Venture Exchange, the settlement of $260,000.00 of debt owed to a former Officer of the Company, through the issuance of an aggregate amount of 701,969 common shares of the Company (the “Payment Shares”) at a deemed price of $0.3704 per Payment Share.
The Interest and Payment Shares will be issued in reliance on certain prospectus exemptions available under securities legislation and 752,136 of the Interest and Payment Shares issued fall within the four-month plus one day statutory hold period.
Cannabis
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
Cannabis
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
Cannabis
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis2 weeks ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 weeks ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis2 weeks ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis7 days ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis6 days ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan6 days ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis2 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa